Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Pável E Olivera, MD, Desirée Campoy, MD, César A Velasquez, MD, Katia Flores, MD, Gabriela S Ene, MD PhD, Tania Canals, MD, Gonzalo Artaza, MD, Maricel Subira, MD, Sofía Vila, Undergraduate student, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2018) 132 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2018-99-119114

Published: 2018

Journal Articles

Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu

Xuejie Chen, Da-Yun Jin, Darrel W. Stafford, Jian-Ke Tie

Blood (2018) 132 (18): 1974–1984.

https://doi.org/10.1182/blood-2018-05-846592

Published: 2018

Includes: Supplemental data

Journal Articles

Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Kyaw Zin Thein, MD MBBS, Lukman Tijani, MD, Thein H. Oo, MD FACP, FRCP

Blood (2016) 128 (22): 1180.

https://doi.org/10.1182/blood.V128.22.1180.1180

Published: 2016

Journal Articles

Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy

Jeffrey A. Jones, MD, Peter Hillmen, MB, ChB, PhD, Steven Coutre, MD, Constantine Tam, MD, Richard R. Furman, MD, Paul M. Barr, MD, Stephen J. Schuster, MD, Thomas J. Kipps, MD, Ian W. Flinn, MD, Ulrich Jaeger, MD, Jan A. Burger, MD PhD, Mei Cheng, PhD, Dana Lee, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Susan O'Brien, MD

Blood (2014) 124 (21): 1990.

https://doi.org/10.1182/blood.V124.21.1990.1990

Published: 2014

Journal Articles

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

Ann Janssens, Francesco Rodeghiero, David Anderson, Beng Chong, Zoltan Boda, Ingrid Pabinger, Libor Cervinek, MD PhD, Xuena Wang, Angela Lopez

Blood (2014) 124 (21): 2774.

https://doi.org/10.1182/blood.V124.21.2774.2774

Published: 2014

Journal Articles

Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy

Petra MG Erkens, PhD, Gregory J Fermann, MD, FACEP, Martin H Prins, MD, Philip S Wells, MD, MSc, Akos F Pap, MSc, Anthonie WA Lensing, MD

Blood (2013) 122 (21): 1139.

https://doi.org/10.1182/blood.V122.21.1139.1139

Published: 2013

Journal Articles

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Bonno van Bellen, MD, Martin Prins, MD, PhD, Luke Bamber, Maria Wang, Anthonie WA Lensing

Blood (2012) 120 (21): 3419.

https://doi.org/10.1182/blood.V120.21.3419.3419

Published: 2012

Journal Articles

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Harry Roger Buller, MD, PhD

Blood (2012) 120 (21): 20.

https://doi.org/10.1182/blood.V120.21.20.20

Published: 2012

Journal Articles

Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Recanalization and Liver Function Evaluation,

Leyre Bento, Ana Rodriguez Huerta, Cristina Pascual, Gloria Pérez Rus, Vega Catalina, Ismael Yepes, Ana María Pérez-Corral, Javier Anguita, Mi Kwon, Jose Luis Diez Martin

Blood (2011) 118 (21): 3358.

https://doi.org/10.1182/blood.V118.21.3358.3358

Published: 2011

Journal Articles

Oral Rivaroxaban for the Acute and Continued Treatment of Symptomatic Venous Thromboembolism. the Einstein-DVT and Einstein-Extension Study

Harry Roger Buller, MD, PhD

Blood (2010) 116 (21): 187.

https://doi.org/10.1182/blood.V116.21.187.187

Published: 2010

Journal Articles

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

Virginia Pérez-Andreu, Vanessa Roldán, Ana Isabel Antón, Nuria García-Barberá, Javier Corral, Vicente Vicente, Rocio González-Conejero

Blood (2009) 113 (20): 4977–4979.

https://doi.org/10.1182/blood-2008-09-176222

Published: 2009

Journal Articles

Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Evaluation of Recanalization and Safety.

Mi Kwon, MD, Ana Rodriguez-Huerta, MD, Cristina Pascual, MD, Manuel Rabadan, MD, Vega Catalina, MD, Noelia Patrignani, MD, Jose L. Diez-Martin, MD, PhD

Blood (2006) 108 (11): 894.

https://doi.org/10.1182/blood.V108.11.894.894

Published: 2006

Journal Articles

The Diagnosis and Monitoring of Superwarfarin Poisoning by Liquid Chromatography-Electrospray Ionisation-Tandem Mass Spectrometry.

Sandrine A.M. Merette, Dominic J. Harrington, Martin J. Shearer, Geoffrey F. Savidge

Blood (2005) 106 (11): 4030.

https://doi.org/10.1182/blood.V106.11.4030.4030

Published: 2005

Journal Articles

Recombinant Activated Factor VII (rFVIIa)-Mediated Normalization of INR Levels Post-Coumadin Overdose.

Wahid T. Hanna, MD

Blood (2005) 106 (11): 4102.

https://doi.org/10.1182/blood.V106.11.4102.4102

Published: 2005

Journal Articles

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity

Laurent Bodin, Céline Verstuyft, David-Alexandre Tregouet, Annie Robert, Liliane Dubert, Christian Funck-Brentano, Patrice Jaillon, Philippe Beaune, Pierre Laurent-Puig, Laurent Becquemont, Marie-Anne Loriot

Blood (2005) 106 (1): 135–140.

https://doi.org/10.1182/blood-2005-01-0341

Published: 2005

Journal Articles

Management of Anticoagulation in Patients Who Requiere Colonoscopy or Gastroscopy: Safety and Efficacy of Sodic Bemiparin (Hibor®.

Maria Amparo Santamaria, MD, Jose Mateo, MD, PhD, Nuria Pujol, MD, PhD, Juan C. Souto, MD, PhD, Mireia Constans, MD, Rosa Ortin, Dolores Llobet, Jordi Fontcuberta, MD, PhD

Blood (2004) 104 (11): 4060.

https://doi.org/10.1182/blood.V104.11.4060.4060

Published: 2004

Journal Articles

Presence of a T383G Mutation in the Vitamin K Epoxide Reductase Gene (VKORC1) in a Patient Resistant to Four Different Vitamin K Antagonists.

Michel-Meyer M.M. Samama, MD, PhD, Laurent L. Bodin, PhD, Marie Helene M.H. Horellou, MD, Florence F. Parent, MD, Anne A. Kereveur, PhD, Philippe P. Beaune, PhD, Marie Anne M.A. Loriot, PhD, Jacqueline J. Conard, PhD

Blood (2004) 104 (11): 4068.

https://doi.org/10.1182/blood.V104.11.4068.4068

Published: 2004

Journal Articles

Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population

José Zarza, José Hermida, Ramón Montes, Ignacio Alberca, Marı́a Luz López, Eduardo Rocha

Blood (2002) 100 (2): 734–735.

https://doi.org/10.1182/blood-2002-03-0821

Published: 2002

Journal Articles

Differential effects of 2C93 and 2C92 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

José Hermida, José Zarza, Ignacio Alberca, Ramón Montes, Marı́a Luz López, Eva Molina, Eduardo Rocha

Blood (2002) 99 (11): 4237–4239.

https://doi.org/10.1182/blood.V99.11.4237

Published: 2002

NARROW

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu

Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy

Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim

Performance Of The Simplified Pesi Score In Patients With Pulmonary Embolism Treated With Rivaroxaban Or Standard Therapy

Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism: A Pooled Analysis of the EINSTEIN DVT and EINSTEIN PE Studies

Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Recanalization and Liver Function Evaluation,

Oral Rivaroxaban for the Acute and Continued Treatment of Symptomatic Venous Thromboembolism. the Einstein-DVT and Einstein-Extension Study

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Evaluation of Recanalization and Safety.

The Diagnosis and Monitoring of Superwarfarin Poisoning by Liquid Chromatography-Electrospray Ionisation-Tandem Mass Spectrometry.

Recombinant Activated Factor VII (rFVIIa)-Mediated Normalization of INR Levels Post-Coumadin Overdose.

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity

Management of Anticoagulation in Patients Who Requiere Colonoscopy or Gastroscopy: Safety and Efficacy of Sodic Bemiparin (Hibor®.

Presence of a T383G Mutation in the Vitamin K Epoxide Reductase Gene (VKORC1) in a Patient Resistant to Four Different Vitamin K Antagonists.

Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population

Differential effects of 2C93 and 2C92 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only